ES2188261T3 - Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides. - Google Patents

Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides.

Info

Publication number
ES2188261T3
ES2188261T3 ES99952903T ES99952903T ES2188261T3 ES 2188261 T3 ES2188261 T3 ES 2188261T3 ES 99952903 T ES99952903 T ES 99952903T ES 99952903 T ES99952903 T ES 99952903T ES 2188261 T3 ES2188261 T3 ES 2188261T3
Authority
ES
Spain
Prior art keywords
prevention
treatment
cancer
tiomolibdate
vacularization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99952903T
Other languages
English (en)
Inventor
George Brewer
Sofia D Merajver
Dimitri The Univer Coucouvanis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Application granted granted Critical
Publication of ES2188261T3 publication Critical patent/ES2188261T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Una composición que comprende un compuesto de tiomolibdato asociado al menos a una primera molécula de carbohidrato.
ES99952903T 1998-09-04 1999-09-03 Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides. Expired - Lifetime ES2188261T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9910398P 1998-09-04 1998-09-04
US10175998P 1998-09-25 1998-09-25

Publications (1)

Publication Number Publication Date
ES2188261T3 true ES2188261T3 (es) 2003-06-16

Family

ID=26795562

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99952903T Expired - Lifetime ES2188261T3 (es) 1998-09-04 1999-09-03 Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides.

Country Status (14)

Country Link
EP (1) EP1107795B1 (es)
JP (1) JP2002524426A (es)
KR (1) KR100702279B1 (es)
CN (1) CN100548383C (es)
AT (1) ATE228375T1 (es)
AU (1) AU773848B2 (es)
CA (1) CA2341752A1 (es)
DE (1) DE69904203T2 (es)
DK (1) DK1107795T3 (es)
ES (1) ES2188261T3 (es)
IL (1) IL141550A0 (es)
NZ (1) NZ510038A (es)
PT (1) PT1107795E (es)
WO (1) WO2000013712A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
WO2003099223A2 (en) * 2002-05-24 2003-12-04 The Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20070292533A1 (en) * 2002-05-24 2007-12-20 Regents Of The University Of Michigan Copper lowering treatment of autoimmune diseases
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
CA2493341A1 (en) 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
AU2004247059A1 (en) * 2003-05-27 2004-12-23 Attenuon L.L.C. Thiotungstate analogues and uses thereof
AU2005217623A1 (en) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
CA2675230A1 (en) * 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
WO2009009622A2 (en) * 2007-07-09 2009-01-15 Pipex Pharmaceuticals, Inc. Pharmaceutical compositions, including attm, and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
KR100972355B1 (ko) * 2008-05-08 2010-07-26 고려전자주식회사 순간식 가스보일러의 온수공급라인용 써모밸브조립체
US10478455B2 (en) 2010-03-30 2019-11-19 Ucl Business Ltd Therapeutic use of tetrathiomolybdate
GB201005394D0 (en) * 2010-03-30 2010-05-12 Magnus Intellectual Property Ltd Therapy
US20160220500A1 (en) * 2014-11-14 2016-08-04 Kent State University Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer
CN108634322A (zh) * 2018-05-16 2018-10-12 刘华 一种预防和调理癌症的方法
AU2019277560B2 (en) * 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders

Also Published As

Publication number Publication date
NZ510038A (en) 2003-10-31
EP1107795B1 (en) 2002-11-27
DK1107795T3 (da) 2003-03-24
WO2000013712A3 (en) 2000-09-28
CA2341752A1 (en) 2000-03-16
KR20010082190A (ko) 2001-08-29
AU773848B2 (en) 2004-06-10
ATE228375T1 (de) 2002-12-15
DE69904203D1 (de) 2003-01-09
JP2002524426A (ja) 2002-08-06
AU6496099A (en) 2000-03-27
DE69904203T2 (de) 2003-08-14
CN100548383C (zh) 2009-10-14
CN1457261A (zh) 2003-11-19
PT1107795E (pt) 2003-04-30
IL141550A0 (en) 2002-03-10
EP1107795A2 (en) 2001-06-20
KR100702279B1 (ko) 2007-04-02
WO2000013712A2 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
ES2188261T3 (es) Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides.
SI2269656T1 (sl) Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
AR046639A1 (es) Combinaciones terapeuticas de anticuerpo anti- igfr1
EP0954340A4 (en) ASSOCIATED TARGET IMMUNOTHERAPY AGAINST CANCER
PL1771474T3 (pl) Inhibitory białka angiopoetyno-4-podobnego, kombinacje i ich zastosowanie
TW200509931A (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
WO2001066123A3 (en) Composition consisting of phy906 and chemotherapeutic agents
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
PL1615952T3 (pl) Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
PL1742644T3 (pl) Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny
IL146125A0 (en) Novel quinones as disease therapies
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
EP1234585A3 (en) Methods and compositions for the prevention or treatment of cancer